Developmental biology

5th Annual Perinatal Stem Cell Society Congress: 2-Day Event (Utah, United States - February 28, 2019 March 1, 2019) - ResearchAndMarkets.com

Retrieved on: 
Friday, February 1, 2019
Stem cells, Health, Branches of biology, Biology, Life sciences, Biotechnology, Induced stem cells, Stem cells, Cloning, Developmental biology, Stem cell

The "5th Annual Perinatal Stem Cell Society Congress" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "5th Annual Perinatal Stem Cell Society Congress" conference has been added to ResearchAndMarkets.com's offering.
  • The field of regenerative medicine is expanding exponentially and the use of perinatal tissue derived products is a major driving force behind this growth.
  • It is the view of the organiser, that the current regulation paradigms for HCT/Ps are not adequate to address the revolutionary growth in the use of perinatal derived tissue and stem cell products taking place in the United States and throughout the world.
  • As the organiser's are comprised of many of the world's leading researchers and clinicians, they have decided to form a working group of industry representatives and society members to develop voluntary guidelines for manufacturers producing 361 regulated perinatal derived tissue and stem cell products.

AgeX Therapeutics to Present at Longevity Leaders Conference, February 4 in London

Retrieved on: 
Thursday, January 31, 2019
Seniors, Stem cells, Health, Biotechnology, Pharmaceutical, Research, Consumer, Science, Branches of biology, Biology, Life sciences, Biotechnology, Cell biology, Stem cells, Cloning, Developmental biology, Cell therapy, Progenitor cell

AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes.

Key Points: 
  • AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes.
  • AgeXs revolutionary longevity platform named induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues.
  • HyStemis AgeXs delivery technology to stably engraft PureStem cell therapies and slowly release iTR molecules in the body.
  • Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

World Stem Cell Summit: PolarityTE to Present Abstract on Regenerative Platform Technology

Retrieved on: 
Wednesday, January 23, 2019
Branches of biology, Biology, Life sciences, Induced stem cells, Biotechnology, Stem cells, Cloning, Developmental biology, Regenerative medicine

SALT LAKE CITY, Jan. 23, 2019 /PRNewswire/ --PolarityTE, Inc. (Nasdaq: PTE) announced today that it will present an abstract highlighting the PolarityTE platform technology at the Regenerative Medicine Foundation World Stem Cell Summit in Miami, Florida on January 24, 2019.

Key Points: 
  • SALT LAKE CITY, Jan. 23, 2019 /PRNewswire/ --PolarityTE, Inc. (Nasdaq: PTE) announced today that it will present an abstract highlighting the PolarityTE platform technology at the Regenerative Medicine Foundation World Stem Cell Summit in Miami, Florida on January 24, 2019.
  • "The World Stem Cell Summit is an excellent opportunity to connect with leaders in the space and contribute to the broader dialog about the future of regenerative medicine.
  • For information on the World Stem Cell Summit, including its history, sponsors and participants, please go to www.worldstemcellsummit.com .
  • POLARITYTE, the POLARITYTE logo, WHERE SELF REGENERATES SELF, and WELCOME TO THE SHIFT are trademarks or registered trademarks of PolarityTE, Inc.

Global Cell Culture (Media, Sera, Reagents) Markets, 2012-2018 & Forecast to 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 14, 2019
Health, Biotechnology, Biology, Biotechnology, Nature, Cell biology, Cloning, Developmental biology, Stem cell, Biopharmaceutical, Cell culture

This report is focused on cell culture used in the research and production of biopharmaceuticals, which includes stem cell therapeutics.

Key Points: 
  • This report is focused on cell culture used in the research and production of biopharmaceuticals, which includes stem cell therapeutics.
  • Worldwide demand for cell culture products for use in the research, development, and production of biotherapeutic drugs is forecast to expand during the forecast period.
  • Growth in the use of cell culture for biological research, vaccine production, the production of therapeutic proteins, and emerging regenerative medicine applications are driving the global cell culture market.
  • Market data provided in Global Cell Culture Markets include:
    Global Cell Culture Market by Segment, 2012-2022 (mil US$) (Media, Sera, Reagents, Total)
    Global Cell Culture Market by Region/Country, 2017
    Global Cell Culture Market by Region/Country, 2022
    Cell Culture Market Share by Company, 2017
    In a market characterized by a high level of concentration, cell culture product suppliers can increase market share and sustain margins by partnering with pharmaceutical companies, or by acquiring smaller producers or companies that manufacture specialty products.

Frequency Therapeutics Completes $42 Million Series B Financing

Retrieved on: 
Monday, January 7, 2019
Stem cells, Health, Biotechnology, Clinical trials, Pharmaceutical, Biology, Nature, Biotechnology, Stem cells, Cell biology, Cloning, Developmental biology, Progenitor cell

Frequency Therapeutics , a clinical-stage biotechnology company creating a new class of drugs based on small molecule stimulation of dormant stem cells within the body which we refer to as Progenitor Cell Activation (PCA), today announced the closing of a $42 million Series B financing, which brings the total capital raised by the Company to $87 million.

Key Points: 
  • Frequency Therapeutics , a clinical-stage biotechnology company creating a new class of drugs based on small molecule stimulation of dormant stem cells within the body which we refer to as Progenitor Cell Activation (PCA), today announced the closing of a $42 million Series B financing, which brings the total capital raised by the Company to $87 million.
  • Yonjin Capital and DF Investments were also new investors in the Series B financing.
  • Existing investors Polaris Founders Capital, Alexandria Venture Investments, CoBro Ventures, Korea Investment Partners and Emigrant Capital also participated in the Series B financing.
  • Frequency Therapeutics develops small molecule drugs to stimulate progenitor cells in the body to reverse biological deficits and restore healthy tissue.

Experimental Stem Cell Therapy Speeds Up Wound Healing in Diabetes

Retrieved on: 
Thursday, January 3, 2019
Biology, Medicine, Developmental biology, Stem cells, Healing, Biotechnology, RTT, KEAP1, Stem-cell therapy, Diabetes mellitus, Regeneration, Wound healing

Published in the January issue of the journal Diabetes , the study showed that the injected stem cells restore a cell signaling pathway called Nrf2/Keap1, recently shown by the NYU team to be disrupted in diabetes.

Key Points: 
  • Published in the January issue of the journal Diabetes , the study showed that the injected stem cells restore a cell signaling pathway called Nrf2/Keap1, recently shown by the NYU team to be disrupted in diabetes.
  • The rebalancing brought on by stem cell therapy, the researchers say, decreased wound healing time to 21 days in treated diabetic mice compared with 32 days in untreated diabetic mice.
  • Previous research by the NYU team had shown that in human diabetes, stem cells do not contribute normally to tissue regeneration.
  • Funding support for the study was provided by the American Diabetes Association Pathway Stop Diabetes Accelerator Award 1-16-ACE-08; National Institutes of Health grants P30 CA016087, S10 OD010584, and S10 OD018338; and New York State Stem Cell Science grant C026719.

BlueRock Therapeutics to Present at the 37th Annual JP Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 2, 2019
Emerging technologies, Regenerative biomedicine, Biology, Regenerative medicine, Tissue engineering, Developmental biology, Stem cells, Stem cell research

CAMBRIDGE, Mass., Jan. 2, 2019 /PRNewswire/ --BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced that Emile Nuwaysir, President and Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 9, 2019 at 10:30 a.m. PT / 1:30 p.m.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 2, 2019 /PRNewswire/ --BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced that Emile Nuwaysir, President and Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 9, 2019 at 10:30 a.m. PT / 1:30 p.m.
  • A replay of the webcast will be available approximately two hours after the event on the Company website.
  • BlueRock Therapeutics is an engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases.
  • BlueRock's cell differentiation technology recapitulates the cell's developmental biology to produce native cell therapies which are further engineered for additional function.

R3 Stem Cell Performs Seven Complimentary Procedures on Military Veterans

Retrieved on: 
Wednesday, January 2, 2019
Biology, Nature, Biotechnology, Stem cells, Induced stem cells, Cloning, Developmental biology

LAS VEGAS, Jan. 2, 2019 /PRNewswire-PRWeb/ -- R3 Stem Cell successfully completed regenerative procedures on seven military veterans recently as part of the R3 Heroes Program.

Key Points: 
  • LAS VEGAS, Jan. 2, 2019 /PRNewswire-PRWeb/ -- R3 Stem Cell successfully completed regenerative procedures on seven military veterans recently as part of the R3 Heroes Program.
  • The stem cell therapies were performed at no cost to any of the Veterans, who were all nominated by friends and family members.
  • Therefore, we created the R3 Heroes program and accepted Veterans with several types of medical conditions for regenerative therapies.
  • The procedures were performed in conjunction with the R3 Stem Cell Training Course, where providers participate in two full days of lectures and viewing procedures.

Global cell therapy instruments market to register a CAGR of 14.4%

Retrieved on: 
Monday, December 31, 2018
Biology, Nature, Stem cells, Biotechnology, Cell biology, Developmental biology, Health, Therapy, Cell therapy, Cell type

Based on the product, the cell therapy instruments market is segmented into consumables, equipment, and systems & software.In 2018, the consumables segment is expected to account for the largest share of the cell therapy instruments market.

Key Points: 
  • Based on the product, the cell therapy instruments market is segmented into consumables, equipment, and systems & software.In 2018, the consumables segment is expected to account for the largest share of the cell therapy instruments market.
  • Based on cell type, the cell therapy instruments market is segmented into human cells and animal cells.In 2018, the human cells segment is expected to account for the largest share of the cell therapy instruments market.
  • Reasons to Buy the Report:
    The report provides insights on the following pointers:
    Market Penetration: Comprehensive information on cell therapy instruments offered by the top 10 players in the global cell therapy instruments market.
  • The report analyzes the markets for various cell therapy instruments across key regions
    Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the global cell therapy instruments market
    Competitive Assessment: In-depth assessment of market shares, strategies, products, and recent developments of the leading players in the global cell therapy instruments market

Study Shows how TAFA2 Protein Induces Stem Cell Migration to Heal Bone Fractures

Retrieved on: 
Monday, December 17, 2018
Biology, Stem cells, Biotechnology, Cell biology, Induced stem cells, Developmental biology, Embryonic stem cell, Induced pluripotent stem cell, Adult stem cell

A new study recently published in STEM CELLS shows a possible way to overcome that.

Key Points: 
  • A new study recently published in STEM CELLS shows a possible way to overcome that.
  • "We identified TAFA2 a recently discovered neurokine involved in cell migration in the central nervous system in a screening experiment using chemo-attraction of MSCs as an end point."
  • The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research.
  • STEM CELLS TRANSLATIONAL MEDICINE ( http://www.StemCellsTM.com ) is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology.